摘要
背景:胶质母细胞瘤(GBM)是一种难以消除的恶性肿瘤,因此迫切需要新的疗法。间充质干细胞(MSC)具有定位受损组织,炎症部位和肿瘤的能力,因此是携带抗肿瘤基因治疗肿瘤的良好候选者。用已经用单纯疱疹病毒胸苷激酶(HSV-TK)基因转导的MSC治疗GBM取得了重大进展,因为在用前药更昔洛韦(GCV)治疗后,MSC可以对肿瘤细胞产生旁观者效应。 目的:在本研究中,我们旨在确定表达HSV-TK的脐带间充质干细胞(MSCTK)联合前药GCV处理是否可以对GBM产生旁观者杀伤作用。 方法与结果:与MSCTK:U87比为1:10、1:100和1:100相比,GCV浓度为2.5μM或250μM,当MSCTK与U87细胞以1:1比例共培养时,产生了25μMGCV更稳定的杀伤效果。与U87细胞共培养的大量MSCTK与MSCTK / GCV系统发挥的更好的旁观者效应相关。我们建立了U87驱动的皮下肿瘤模型和脑颅内肿瘤模型,以评估MSCTK / GCV系统对皮下和颅内肿瘤的效率,发现MSCTK / GCV在两种模型中均有效。 MSCTK与肿瘤细胞的比例在该治疗效果中起关键作用,更高的MSCTK / U87比发挥更好的效果。 结论:该研究表明MSCTK / GCV系统对GBM肿瘤细胞具有较强的旁观者作用,该系统可能是GBM术后治疗的有希望的辅助方法。
关键词: 间充质干细胞,胶质母细胞瘤,HSV-TK,旁观者效应,局部基因治疗,脐带,GCV。
图形摘要
[http://dx.doi.org/10.1016/j.pneurobio.2018.09.007] [PMID: 30290215]
[http://dx.doi.org/10.2174/1566523217666170605115829] [PMID: 28578643]
[http://dx.doi.org/10.1016/j.semcancer.2018.09.007] [PMID: 30266571]
[http://dx.doi.org/10.3390/cancers11020190]
[http://dx.doi.org/10.1016/j.pharmthera.2015.05.005] [PMID: 25944528]
[http://dx.doi.org/10.2174/156652311795684722]
[http://dx.doi.org/10.1166/jbn.2018.2642] [PMID: 30305211]
[http://dx.doi.org/10.1021/acsami.9b00893] [PMID: 30900870]
[http://dx.doi.org/10.1038/s41586-018-0733-7] [PMID: 30429614]
[http://dx.doi.org/10.1016/j.actbio.2018.09.015] [PMID: 30223091]
[http://dx.doi.org/10.1111/jpi.12535] [PMID: 30372554]
[http://dx.doi.org/10.1088/1758-5090/aa7484] [PMID: 28589925]
[http://dx.doi.org/10.7150/thno.26981]
[http://dx.doi.org/10.1016/j.yexcr.2013.04.002] [PMID: 23578766]
[http://dx.doi.org/10.2174/1566523218666180913152615] [PMID: 30209999]
[http://dx.doi.org/10.1021/acsami.8b05363] [PMID: 29905067]
[http://dx.doi.org/10.1089/scd.2018.0132] [PMID: 30484393]
[http://dx.doi.org/10.2174/1566523218666180214094253] [PMID: 29446737]
[http://dx.doi.org/10.2174/1574888X09666140923101110] [PMID: 25248677]
[http://dx.doi.org/10.1039/C8BM01657G] [PMID: 30942200]
[http://dx.doi.org/10.2174/1566523217666170510162459] [PMID: 28494738]
[http://dx.doi.org/10.1016/j.tice.2019.01.006] [PMID: 30947959]
[http://dx.doi.org/10.1016/j.tice.2018.08.012] [PMID: 30309499]
[http://dx.doi.org/10.1016/j.msec.2019.02.092] [PMID: 30948058]
[http://dx.doi.org/10.1016/j.bbi.2019.04.010] [PMID: 30953770]
[http://dx.doi.org/10.1186/1741-7007-11-55]
[http://dx.doi.org/10.1155/2018/7318513] [PMID: 29535779]
[http://dx.doi.org/10.1016/j.tox.2019.03.017] [PMID: 30953668]
[http://dx.doi.org/10.1080/15384047.2018.1523094] [PMID: 30257140]
[http://dx.doi.org/10.1016/j.tiv.2019.03.041] [PMID: 30946969]
[http://dx.doi.org/10.1002/jcp.22511] [PMID: 21442622]
[http://dx.doi.org/10.3727/096368915X687462] [PMID: 25695620]
[http://dx.doi.org/10.1155/2018/5912194]
[http://dx.doi.org/10.1089/scd.2012.0486]
[http://dx.doi.org/10.1007/s11010-013-1836-y] [PMID: 24104453]
[http://dx.doi.org/10.1155/2014/109389]
[http://dx.doi.org/10.1038/s41467-018-08096-8]
[http://dx.doi.org/10.1097/j.pain.0000000000001420] [PMID: 30335680]
[http://dx.doi.org/10.1186/s13058-017-0882-x]
[http://dx.doi.org/10.1016/j.molimm.2018.06.267] [PMID: 30007547]
[http://dx.doi.org/10.1016/j.actbio.2019.03.048] [PMID: 30930305]
[http://dx.doi.org/10.1002/jcp.26094] [PMID: 28703313]
[http://dx.doi.org/10.1007/s00406-019-01009-w] [PMID: 30923939]
[http://dx.doi.org/10.2174/1566523214666140424152734] [PMID: 24766134]
[http://dx.doi.org/10.1016/j.jpsychires.2019.03.007] [PMID: 30904785]
[http://dx.doi.org/10.1002/sctm.18-0039] [PMID: 30887735]
[http://dx.doi.org/10.3390/cancers11020264]
[http://dx.doi.org/10.1016/j.omto.2017.06.001]
[http://dx.doi.org/10.1016/j.canlet.2009.08.028] [PMID: 19765892]
[http://dx.doi.org/10.1097/SLA.0b013e3182368c4f] [PMID: 22042469]
[http://dx.doi.org/10.1016/j.canlet.2017.11.025] [PMID: 29175461]
[http://dx.doi.org/10.1016/j.jconrel.2015.05.007] [PMID: 25966361]
[http://dx.doi.org/10.1016/j.scr.2012.08.002] [PMID: 23022734]
[http://dx.doi.org/10.1002/ijc.32230] [PMID: 30801698]
[http://dx.doi.org/10.3390/ijms20040810]
[http://dx.doi.org/10.1016/j.jpsychores.2018.11.009] [PMID: 30654990]